MPA Meningioma Risk: Key Insights and Implications

By Crystal Lubbe

January 22, 2025

The South African Health Products Regulatory Authority (SAHPRA) has issued a clarification regarding the benefits and risks associated with medroxyprogesterone acetate (MPA), a synthetic form of the hormone progesterone. This substance is used for contraception, managing endometriosis-associated pain, and treating certain cancers. SAHPRA has updated the safety warnings for MPA-containing products to include the potential MPA meningioma risk based on epidemiological studies conducted in France and the United States.

Key Insights

SAHPRA identified an increased risk of meningioma associated with prolonged use of MPA. Although the absolute risk remains low, only 32 cases have been reported globally over the past 20 years. MPA appears in various products, such as Depo-Provera, Provera, Petogen, Medroxyprogesterone Mylan, Sayana, Omrastoz, Trivina, and Triclogyn. Healthcare professionals commonly prescribe these products for contraception, managing endometriosis, and providing palliative care for certain cancers. Providers should monitor patients for signs of meningioma and stop MPA use if diagnosed, particularly when used for non-oncological reasons. Patients should discuss potential side effects with their healthcare providers. SAHPRA also urges the public and healthcare professionals to report any suspected adverse drug reactions related to MPA.

Background Context

This update stems from regulatory actions in Europe, prompted by studies identifying an increased risk of meningioma with prolonged MPA use. Similar risks were observed with other progestogens, such as medrogestone and promegestone, though these are not currently marketed in South Africa. Meningiomas are typically benign tumors that develop from the membranes surrounding the brain and spinal cord. They are more common in women and tend to occur in middle-aged and older adults.

Implications

The updated safety warnings on MPA products may change how patients and providers assess risks and benefits. While MPA’s benefit-risk profile is still favorable, the added meningioma risk could, therefore, affect treatment decisions. This may lead to higher monitoring costs and revised treatment plans. Moreover, healthcare systems may need more resources to monitor and manage potential meningioma cases. As a result, this could strain budgets and impact resource allocation. Additionally, patient compliance might decline if concerns about side effects grow. Consequently, clear education and counseling will be vital to keep patients on treatment.

Furthermore, enhanced reporting of adverse reactions is essential to track meningioma cases linked to MPA. Stronger pharmacovigilance practices will, in turn, improve safety and management. Overall, SAHPRA’s update reinforces the need for active monitoring and safety measures. These efforts ensure safer treatments and better health outcomes.

Reference url

Recent Posts

oral cancer East Africa
   

Oral Cancer in East Africa: The Need for Early Detection

💡 Did you know that Toombak use is a leading risk factor for oral cancer in East Africa?

A recent scoping review sheds light on the shocking prevalence of oral cancer in the region, emphasising the urgent need for public health interventions and improved early detection strategies. Enhancing awareness around risk factors like Toombak, tobacco, and alcohol for tackling this growing health crisis.

Curious about the key insights and their implications for health economics? Look into the full article to find out more!

#SyenzaNews #HealthEconomics #Oncology #GlobalHealth

Novartis patent cliff layoffs
     

Engineering Resilience: Mastering Pharma Patent Expiration Strategy

🚨 Are you still reacting to pharmaceutical patent expirations with layoffs and litigation, or are you ready to engineer a strategy that turns the patent cliff into your next competitive edge?

Patent expirations don’t have to derail your pharma portfolio. Learn how to outmaneuver generics and transform challenges into advantages. Dive into our latest insights and take control today.

#SyenzaNews #pharmaceuticals #innovation #PharmaStrategy #patentcliffs

diabetes medicine access
               

Improving Diabetes Medicine Access: Key Changes in the Pharmaceutical Benefits Scheme

🚀 Are we on the verge of a breakthrough in diabetes medication accessibility?

The latest updates to the Pharmaceutical Benefits Scheme (PBS) are set to transform type 2 diabetes management by expanding access to essential medicines like empagliflozin and streamlining the prescribing process for glucagon-like peptide 1 receptor agonists (GLP-1 RAs). These changes not only prioritize equity for high-risk populations but also align with global trends in cost-effective healthcare.

Dive deeper into how these revisions could reshape diabetes care and promote better health outcomes for all.

#SyenzaNews #HealthcareInnovation #healthcare #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.